Prurigo nodularis - I-Prurigo Nodularis
☆ Emiphumeleni ka-2022 ye-Stiftung Warentest evela eJalimane, ukwaneliseka kwabathengi nge-ModelDerm bekungaphansi kancane kunokuxhumana okukhokhelwayo kwe-telemedicine.
References
I- Prurigo nodularis yisimo sesikhumba esihlala isikhathi eside esibonakala ngamaqhubu namaqhuqhuva amaningi aqinile, ngokuvamile atholakala ezingxenyeni ezingaphandle zezingalo nemilenze. Lawa maqhuqhuva angahluka ngombala ukusuka kowenyama ukuya kobomvana futhi ayaluma kakhulu. Zingathinta abantu banoma iyiphi iminyaka futhi zivame ukuxhunyaniswa nezinye izimo zesikhumba ezibangela ukulunywa okungapheli, njenge-atopic dermatitis. Izinketho zokwelapha zihlanganisa imithi eqinile yokulwa nokulunywa, izidakamizwa ezithinta isimiso somzimba sokuzivikela ezifweni, nemithi eqondise isimiso sezinzwa. Ukuphatha i-prurigo nodularis ngokuvamile kuhilela ukwelashwa kwesikhathi eside.
Prurigo nodularis is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group. It is commonly associated with another disease such as atopic dermatitis or any dermatoses associated with chronic pruritus. The therapeutic approach is wide-arrayed ranging from treatments that act as - potent antipruritics, immunomodulators, and neuromodulators. Treatment in an established case is prolonged and improving patient compliance with education and counseling is important.
Prurigo nodularis is a chronic disorder of the skin that is classically seen as multiple, firm, flesh to pink colored papules, plaques and nodules commonly located on the extensor surfaces of the extremities. The lesions are very pruritic and can occur in any age group. It is commonly associated with another disease such as atopic dermatitis or any dermatoses associated with chronic pruritus. The therapeutic approach is wide-arrayed ranging from treatments that act as - potent antipruritics, immunomodulators, and neuromodulators. Treatment in an established case is prolonged and improving patient compliance with education and counseling is important.
Ukwelashwa ngokuvamile kuhilela ukusebenzisa okhilimu noma imijovo ye-steroids endaweni ethintekile. Ezimweni ezinzima kakhulu noma ezinenkani, ukwelashwa okufana nokwelashwa okulula noma imithi ecindezela amasosha omzimba kungase kudingeke. I-Thalidomide ne-Lenalidomide yizinketho ezimweni ezinzima, kodwa zingaba nemiphumela emibi kakhulu. Ukwelashwa okusha (opioid receptor antagonists, neurokinin-1 receptor antagonists) kubonisa isithembiso ekwelapheni i-prurigo nodularis ngemiphumela engemihle embalwa uma kuqhathaniswa ne-thalidomide noma i-lenalidomide.
Treatment typically relies on the use of topical or intralesional steroids, though more severe or recalcitrant cases often necessitate the use of phototherapy or systemic immunosuppressives. Thalidomide and lenalidomide can both be used in severe cases; however, their toxicity profile makes them less favorable. Opioid receptor antagonists and neurokinin-1 receptor antagonists represent two novel families of therapeutic agents which may effectively treat PN with a lower toxicity profile than thalidomide or lenalidomide.
Treatment typically relies on the use of topical or intralesional steroids, though more severe or recalcitrant cases often necessitate the use of phototherapy or systemic immunosuppressives. Thalidomide and lenalidomide can both be used in severe cases; however, their toxicity profile makes them less favorable. Opioid receptor antagonists and neurokinin-1 receptor antagonists represent two novel families of therapeutic agents which may effectively treat PN with a lower toxicity profile than thalidomide or lenalidomide.
I- Chronic prurigo yisimo sesikhumba esibonakala ngokuluma okuhlala isikhathi eside (okuthatha ngaphezu kwamaviki angu-6) , izilonda esikhumbeni ezihambisana nokunwaya, kanye nomlando wokunwaya njalo. Kubandakanya i-neuroinflammation kanye ne-fibrosis esikhumbeni.
Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching.
Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching.
Prurigo nodularis inkinga yesikhumba ehlala isikhathi eside ephawulwa ngamaqhuqhuva alumayo. Asazi ngempela ukuthi kubangelwa yini, kodwa kubonakala sengathi izinkinga zokuzivikela komzimba nezinzwa zinendima emjikelezweni wokulunywa. Njengamanje, azikho izindlela zokwelapha ezigunyazwe i-US FDA eziqondiswe ngqo i-prurigo nodularis.
Prurigo nodularis is a long-lasting skin problem marked by itchy nodules. We don't know exactly what causes it, but it seems that immune and nerve issues play a role in the itch-scratch cycle. Right now, there aren't any treatments approved by the US FDA specifically for prurigo nodularis.
Prurigo nodularis is a long-lasting skin problem marked by itchy nodules. We don't know exactly what causes it, but it seems that immune and nerve issues play a role in the itch-scratch cycle. Right now, there aren't any treatments approved by the US FDA specifically for prurigo nodularis.
○ Ukwelashwa - Izidakamizwa ze-OTC
Ukugeza indawo enesilonda ngensipho akusizi ngalutho futhi kungenza kube kubi nakakhulu. Amafutha e-OTC steroid angasiza ekudambiseni izimpawu, kodwa ngokuvamile adinga ukufakwa amasonto ambalwa ukuze abe ngcono. Ukuqhubeka nokuthatha ama-antihistamine nakho kusiza ekudambiseni ukulunywa.
#OTC steroid ointment
#OTC antihistamine
○ Ukwelashwa
#Intralesional triamcinolone injection